New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag

New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag

Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that com...

Full description

Saved in:
Bibliographic Details
Published in:Kardiovaskuli͡a︡rnai͡a︡ terapii͡a︡ i profilaktika Vol. 18; no. 6; pp. 80 - 87
Main Authors: Ilyin, N. V., Ivanov, K. I., Martynyuk, T. V.
Format: Journal Article
Language:English
Published: SILICEA-POLIGRAF» LLC 22-12-2019
Subjects:
combination therapy
pulmonary arterial hyperten¬sion
selexipag
specific therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that combination therapy with PAH-specific medications can significantly inhibit the development of the disease. Therefore, in modern guidelines, combination therapy is considered as a treatment standard for a significant proportion of patients with PAH. This publication presents a modern view of the selexipag practical using in early combination therapy in patients with PAH.
AbstractList Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that combination therapy with PAH-specific medications can significantly inhibit the development of the disease. Therefore, in modern guidelines, combination therapy is considered as a treatment standard for a significant proportion of patients with PAH. This publication presents a modern view of the selexipag practical using in early combination therapy in patients with PAH.
Author Martynyuk, T. V.
Ivanov, K. I.
Ilyin, N. V.
Author_xml – sequence: 1
  givenname: N. V.
  orcidid: 0000-0001-6747-1585
  surname: Ilyin
  fullname: Ilyin, N. V.
  organization: Republican Hospital № 1 — National Center of Medicine
– sequence: 2
  givenname: K. I.
  orcidid: 0000-0002-4084-6612
  surname: Ivanov
  fullname: Ivanov, K. I.
  organization: Republican Hospital № 1 — National Center of Medicine
– sequence: 3
  givenname: T. V.
  orcidid: 0000-0002-9022-8097
  surname: Martynyuk
  fullname: Martynyuk, T. V.
  organization: National Medical Research Center of Cardiology
BookMark eNo9kU1OHDEQha0IpAw_Z4gv4FB2d9vuZYRCGAklLGBt2Z7yYNTTbtkOCTsOwQk5CR5ArOrv6ZPqvSNyMKcZCfnG4TsftBjPuBKaaQ3ABPCRSaaBafWFrIRsI3AxHJDVp-grOS3lHgC4VkMn-hVJv_EfrRlt3eFcaVpqTHOhIWW6_J12abb5kdpcMUc70bvHBVs_lyaiL0_PtN4hDTGXSgtO6Gt8QLq-Zhk9LrUx7DbN8eP6Py52e0IOg50Knn7UY3J78fPm_JJd_fm1Pv9xxbzgSjGp_Nj5jYAeQ3BOj94JD6JDJThwUHoMQUrk1inJB2HVqN2oBY5-wKA63h2T9Tt3k-y9WXLctUdMstG8LVLemvZV9BOa3mm0nXObjZT9oKS1WjWDWgfQd71rLPXO8jmVkjF88jiYtxjM3mGzd9jsYzDSaDBada_R3H9C
CitedBy_id crossref_primary_10_1080_13880209_2021_2005636
crossref_primary_10_38109_2225_1685_2020_2_54_60
crossref_primary_10_38109_2075_082X_2024_1_21_28
Cites_doi 10.1007/s40256-016-0209-9
10.1183/13993003.02493-2016
10.1002/ejhf.1375
10.2146/ajhp160798
10.1183/09031936.00137511
10.1056/NEJMoa1413687
10.26442/00403660.2019.01.000024
10.1093/eurheartj/ehv317
10.1056/NEJMoa1503184
ContentType Journal Article
DBID AAYXX
CITATION
DOA
DOI 10.15829/1728-8800-2019-6-80-87
DatabaseName CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
EISSN 2619-0125
EndPage 87
ExternalDocumentID oai_doaj_org_article_4b8ea3bbdd664576aa8701857600434b
10_15829_1728_8800_2019_6_80_87
GroupedDBID 29B
5GY
642
AAYXX
ABDBF
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BCNDV
CITATION
EAP
EAS
ESX
GROUPED_DOAJ
VCL
VIT
ID FETCH-LOGICAL-c2177-67c93cd204effbb89cb2c023e721010789ff66e1ab76152a798b982e9c5ef7313
IEDL.DBID DOA
ISSN 1728-8800
IngestDate Mon Oct 21 19:33:15 EDT 2024
Fri Aug 23 03:19:27 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2177-67c93cd204effbb89cb2c023e721010789ff66e1ab76152a798b982e9c5ef7313
ORCID 0000-0001-6747-1585
0000-0002-4084-6612
0000-0002-9022-8097
OpenAccessLink https://doaj.org/article/4b8ea3bbdd664576aa8701857600434b
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_4b8ea3bbdd664576aa8701857600434b
crossref_primary_10_15829_1728_8800_2019_6_80_87
PublicationCentury 2000
PublicationDate 2019-12-22
PublicationDateYYYYMMDD 2019-12-22
PublicationDate_xml – month: 12
  year: 2019
  text: 2019-12-22
  day: 22
PublicationDecade 2010
PublicationTitle Kardiovaskuli͡a︡rnai͡a︡ terapii͡a︡ i profilaktika
PublicationYear 2019
Publisher SILICEA-POLIGRAF» LLC
Publisher_xml – name: SILICEA-POLIGRAF» LLC
References ref13
ref12
ref11
ref10
ref2
ref1
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref3
  doi: 10.1007/s40256-016-0209-9
– ident: ref4
– ident: ref12
  doi: 10.1183/13993003.02493-2016
– ident: ref13
  doi: 10.1002/ejhf.1375
– ident: ref8
  doi: 10.2146/ajhp160798
– ident: ref5
– ident: ref6
– ident: ref7
  doi: 10.1183/09031936.00137511
– ident: ref11
  doi: 10.1056/NEJMoa1413687
– ident: ref2
  doi: 10.26442/00403660.2019.01.000024
– ident: ref1
  doi: 10.1093/eurheartj/ehv317
– ident: ref9
  doi: 10.1056/NEJMoa1503184
– ident: ref10
SSID ssj0001875324
Score 2.1588597
Snippet Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early...
SourceID doaj
crossref
SourceType Open Website
Aggregation Database
StartPage 80
SubjectTerms combination therapy
pulmonary arterial hyperten¬sion
selexipag
specific therapy
Title New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
URI https://doaj.org/article/4b8ea3bbdd664576aa8701857600434b
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NS8QwEA26Jy-iqLh-kYPXsG2abZKjH7usFxFU8BaSNtEF2S5dC3rzR_gL_SXOpLXszYu3kpZS3kwn77XDG0LOnc2gBFrOhC4kE1nJmR6HwHRpPU-DFcriN93Zvbx9UtcTtMnpR31hT1hrD9wCNxJOeZs5V5Z5LoAcWwsZhgZGOf7EEi5W30Stian4dQVpeDvRVnLFIEmTrrlrrLge9YuQJKlmaMnLsKlubWtac_CPW810h2x3HJFetM-2SzbqZo9UUI5o3xZOq7YZhQLnpMvmFZLJ1h80NmhCRtEXkJd1bE6vFvT784sCz6NhDlSPruLkGyhy9OaOQb3zS5Dd1D5X6KEbz77Pocrsk8fp5OFqxrppCawAWSFZLgudFSVPhA_BOaULxwvYkT1oPBBdUukQ8tyn1klgMdxKrZxW3Oti7IPM0uyADBbVwh8SmkgnvA4uEYLHgwCvulCFADbAtXdDkvwCZZatKYZBMYHYGsTWILYGsTW5UYlRckguEdD-cnS1jgsQa9PF2vwV66P_uMkx2YpBTznj_IQM3urGn5LNVdmcxRz6Ac5cyF0
link.rule.ids 315,782,786,866,2108,27935,27936
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+treatment+options+for+pulmonary+arterial+hypertension+%E2%80%94+the+first+selective+IP-receptor+agonist+selexipag&rft.jtitle=Kardiovaskuli%CD%A1a%EF%B8%A1rnai%CD%A1a%EF%B8%A1+terapii%CD%A1a%EF%B8%A1+i+profilaktika&rft.au=Ilyin%2C+N.+V.&rft.au=Ivanov%2C+K.+I.&rft.au=Martynyuk%2C+T.+V.&rft.date=2019-12-22&rft.issn=1728-8800&rft.eissn=2619-0125&rft.volume=18&rft.issue=6&rft.spage=80&rft.epage=87&rft_id=info:doi/10.15829%2F1728-8800-2019-6-80-87&rft.externalDBID=n%2Fa&rft.externalDocID=10_15829_1728_8800_2019_6_80_87
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1728-8800&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1728-8800&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1728-8800&client=summon